Sonendo Inc

Hello, and welcome to Sunendo's third quarter earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session at the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Louisa Smith from Gilmartin Group for a few introductory comments.

Thanks, operator. Good afternoon, and thank you for participating in today's call. Joining me from Sunendo are Bjorn Berghain, President and CEO, and Michael Watts, CFO. Earlier today, Sunendo released financial results for the quarter ended September 30th, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws. which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made on this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including those relating to our operating trends and future financial performance, the impact of COVID-19 on our business, expense management, Expectations for hiring, growth in our organization, market opportunity, revenue guidance, commercial expansion, and product pipeline development are based on our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and descriptions of the risk and uncertainties associated with our business, please refer to the risk factors section of our most recent annual report on Form 10-K, filed March 8, 2023, with the Securities and Exchange Commission and available on EDGAR and in our other public reports filed periodically with the SEC. This conference call contains time-sensitive information and is accurate only as of the live broadcast on November 8, 2023. Sunendo disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will now turn the call over to Bjorn.

Thanks, Louisa. Good afternoon, everyone, and thank you for joining us today. For this call, I will start with some commentary about third quarter performance, business highlights, and forward-looking strategy before turning the call over to Mike to provide additional detail regarding financial results. We will finish with Q&A. The third quarter saw steady capital placements and revenues in line with our initial estimates totaling $10.4 million and representing growth of 6% year over year. Procedure instrument revenue grew 7% year-over-year to $5.1 million in the third quarter. Console revenue growth was in line with the prior year, totaling $2.1 million for the third quarter of 2023. As we have seen in prior years, our annual sales cadence for 2023 is shaping up to be reflective of the seasonality we typically encounter. The first and third quarters are generally lighter in console placements than Q2 and Q4. attributable to buying patterns common in MedTech capital equipment. The third quarter of 2023 was no different. We saw lingering macroeconomic pressures in addition to the typical effects of extended vacation schedules and summer slowdowns. However, unlike previous years, we experienced a slowing of utilization and consumable sales in the latter part of the quarter. Consumable sales often rebound from the summer seasonality but this September proved to be lighter in terms of volumes. As we have visibility to procedures at the practice level, we believe the decline was experienced broadly across many of our endodontist customers, not just a reduction in general procedures. Many of our doctors reported a decline in patient numbers, as was seen in other areas of the dental market. As we move into Q4, we're seeing procedures stabilize from the Q3 exit, but we will continue to monitor demand. While the majority of endodontic procedures are non-elective, there remains a certain number that are asymptomatic, which may result in patients delaying treatment and ultimately a shift in patient volumes. In relation to console placement trends, we continue to see a lengthening sales cycle and therefore have implemented new programs to counter these effects that I'll expand upon later. Despite these dynamics, we were pleased with general solid sales figures and remain optimistic about continued adoption of the general rate procedure. Going forward, we're committed to three fundamental pillars to drive Sunendo's success. Simply stated, those are one, growing top line revenue, two, improving margin profiles, and three, prioritizing cash preservation. I'd like to spend a moment to detail our initiatives as they relate to each of these three pillars and the internal steps we've taken to ensure we execute against our plans for the remainder of the year and into 2024. As for revenue growth, we recently announced an expansion into the DSO channel and the signing of partnership agreements with two specialist DSO groups. DSOs represents an important segment within the industry, and these partnership agreements will greatly expand access to the general procedure in endodontic offices nationwide. For example, These two agreements now enable us to sell into nearly 200 new target accounts. Outside of the DSO strategy, we've begun a limited trial or evaluation program for practitioners to fully experience the general technology in their offices at no initial upfront cost. This allows doctors and their staff to realize firsthand the clinical practice and patient benefits for the general system before committing to a purchase. While we're still in the early stages of this initiative, we're noting significant interest and positive impact on moving customers through the funnel more rapidly. We believe the continuance of these trial periods will build upon momentum in our sales pipeline and serve as important catalysts to shorten the selling cycle on a go-forward basis. Turning to utilization and consumer revenue, we have a recent announcement regarding clean flow clearance for interior procedures and important improvements with our Gen 2 version, we believe the improved clinical workflow enhances the already significant benefits of the Genway procedure. With one procedure instrument, we have simplified our training programs to ensure customer success from the start. With regards to margin improvement, we continue to focus on two drivers. First, accelerating our path to full conversion to the clean flow procedure instrument, which we anticipate being essentially complete as we enter 2024. Second, we completed a transition to in-house G4 assembly that have now manufactured over 100 consoles in our facilities, enabling us to leverage our existing capabilities as we scale our business. Combined, these initiatives provide us much more control in future cost reductions, including gaining economies of scale, simplifying the product portfolio, and achieving supply chain consolidation, all of which ultimately results in higher contribution margins. Moving to cash preservation, Sunenda remains committed to responsible and measured spending to retain a healthy balance sheet. In the third quarter, we were able to reduce quarterly operating cash burn by nearly 30% sequentially from Q2 and 35% year-over-year. We will continue to make necessary adjustments to right-size the business without compromising long-term growth opportunities. Earlier this week, we completed a reduction force that, combined with reductions announced earlier in the year, will conserve approximately $6 to $8 million in the next 12 months and allow the company to leverage operational efficiencies in a more meaningful way. While these decisions are never easy or taken lightly, we believe they are appropriate in this environment. Our customers will not be impacted by any of these changes. Lastly, we're thrilled to announce the submission of our 510K application to the FDA for the use of the general wave system for cavity indications, a future application beyond our current market of root canal therapy and one that will significantly increase our total addressable market. This is a significant step forward in solving tooth decay in millions of patients worldwide. At the same time, we don't want to get ahead of ourselves in terms of quantifying this opportunity or even the timeline in which we might see the revenue pull through with respect to the application of our technology for cavity indication. Needless to say, we remain incredibly optimistic about our long-term growth opportunities and the sustainable platform we're building to capitalize on the potential that exists within the endodontic and broader dental market. I will now turn the call over to Michael Watts, Sunendo's Chief Financial Officer, and then return for some closing comments after the question and answer session. Mike?